Results 261 to 270 of about 93,087 (311)
Some of the next articles are maybe not open access.
Allogeneic Stem Cell Transplantation
Transplantation Proceedings, 2005Allogeneic stem cell transplantation (HSCT) requires the harvest of an adequate number of stem cells (SC) from a histocompatible donor and their infusion into a patient following a conditioning regimen. During the past 35 years, the role of HSCT has changed from an experimental procedure for terminally ill patients to a curative treatment.
BOSI, ALBERTO, BARTOLOZZI B, GUIDI S.
openaire +3 more sources
Innovations in allogeneic stem-cell transplantation
Seminars in Hematology, 2000Allogeneic bone marrow transplantation (BMT) is associated with prolonged periods of neutropenia and thrombocytopenia, which can lead to severe infections and bleeding complications. Transplantation-related side effects might be ameliorated by use of cytokine-mobilized peripheral blood progenitor cells (PBPC) Instead of bone marrow.
J F, DiPersio +6 more
openaire +2 more sources
Allogeneic blood stem cell transplantation
European Journal of Cancer, 2009The development of haematopoietic blood stem cell transplantation after World War II was stimulated by the concept of having an efficient treatment against irradiation damage after the military use of nuclear weapons and after accidents in nuclear plants.
Gerhard, Ehninger, Martin, Bornhäuser
openaire +2 more sources
Allogeneic stem-cell transplantation for myelofibrosis
Current Opinion in Hematology, 2017Purpose of review Allogeneic hematopoietic stem-cell transplantation (HSCT) remains the only curative therapy for myelofibrosis. The number of HSCTs performed for this indication has been steadily increasing over the past years, even after the approval of the Janus kinase (JAK) inhibitor, ruxolitinib.
Noa, Lavi +2 more
openaire +2 more sources
Improving allogeneic stem cell transplantation in myelofibrosis
International Journal of Hematology, 2022In this review, we will outline dimensions in which outcome of patients with myelofibrosis undergoing curative treatment can be optimized: patient selection, transplant procedure, and posttransplant prevention or treatment of relapse. For patient selection, fortunately, as with several other hematologic malignancies, the management of patients with ...
Nico, Gagelmann, Nicolaus, Kröger
openaire +2 more sources
Allogeneic Hematopoietic Stem Cell Transplantation
Therapeutic Apheresis and Dialysis, 2003Abstract: More than 30 years have passed since the first clinical application of allogeneic bone marrow transplantation to treat hematological diseases. In recent years, the availability of peripheral blood and cord blood as additional sources of stem cells other than bone marrow has expanded the applicability of hematopoietic stem cell transplantation.
Shunro, Kai, Hiroshi, Hara
openaire +2 more sources
[Allogeneic stem cell transplantation].
Nihon rinsho. Japanese journal of clinical medicine, 2002Over the last two decades, four major therapeutic approaches have dramatically changed the prognosis in chronic myelogenous leukemia(CML). Those include allogeneic stem cell transplantation, interferon-alpha based regimen, donor-leukocyte infusions, and the revolutionary BCR/ABL tyrosine kinase inhibitor such as STI571.
K, Sawafuji, S, Okamoto
openaire +3 more sources
Allogeneic stem-cell transplantation for renalcellcancer
The Lancet Oncology, 2004Metastatic renal-cell carcinoma (RCC) is resistant to chemotherapy, and patients with this disease have a poor outlook. Immunotherapy by use of cytokines and vaccines against tumour antigens has shown encouraging results in a small group of patients. Advances in the understanding of the graft-versus-tumour effect in haematological malignant disorders ...
Lyndon, Gommersall +5 more
openaire +2 more sources
Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy [PDF]
Brain, 2015 Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal encephalomyopathy, a rare fatal autosomal recessive disease due to TYMP mutations that result in thymidine phosphorylase deficiency.
Jörg Halter +2 more
exaly +2 more sources
Allogeneic Stem Cell Transplantation for Multiple Myeloma
Hematology/Oncology Clinics of North America, 2008Prospective trials comparing tandem autologous stem cell transplantation (ASCT) with ASCT followed by allogeneic stem cell transplantation (AlloSCT) have shown mixed results with regard to progression-free and overall survival rates. Thus, AlloSCT, although a potentially curative treatment, is not regarded as a standard treatment for multiple myeloma ...
openaire +2 more sources